Publication | Closed Access

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

Carcinoid SyndromeOctreotide Long-acting RepeatableMedicinePharmacologyPathologyCancer TreatmentNeuroendocrine TumorsOncologyAdvanced Neuroendocrine TumoursCancer ResearchEndocrine-related Cancer